Ireland-based Horizon Pharma has entered into a definitive agreement to acquire rare-disease company Raptor Pharmaceutical for approximately $800m.
Under the transaction, Horizon will pay $9 per share in cash for all of the issued and outstanding shares of Raptor.
Go deeper with GlobalData
The company intends to finance the transaction through $675m of external debt along with cash on hand.
Horizon Pharma chairman, president and chief executive officer Timothy P. Walbert said: "The proposed acquisition of Raptor furthers our commitment to helping people with rare diseases and is a significant step in advancing our strategy to expand our rare disease business.
"Along with the potential for accelerated revenue growth, the addition of Raptor strengthens our US orphan business and provides a platform to expand our orphan business in Europe and other key international markets.
See Also:
"We look forward to working with new patient communities and building on the success of the Raptor team."
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe acquisition is expected to strengthen Horizon's focus on rare diseases and provides expansion into Europe and other international markets.
The transaction is subject to the satisfaction of customary closing conditions and regulatory approvals, including antitrust approval in the US, and is expected to close in the fourth quarter of this year.
Earlier this year, Horizon acquired Crealta Holdings for $510m.
Raptor has previously disclosed that it expects the total net sales guidance for the full year of 2016 to be $125m to $135m, including both procysbi and quinsair.
The company’s procysbi is the first cystine-depleting agent approved in the US for the treatment of nephropathic cystinosis (NC), a rare metabolic disorder.
Quinsair is approved in Europe and Canada for the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa in adults with cystic fibrosis.
BofA Merrill Lynch, J.P. Morgan, Jefferies LLC and Cowen and Company, LLC are financial advisors to Horizon Pharma, while Centerview Partners LLC and Leerink Partners LLC are financial advisors to Raptor.
